Final tranche puts Inocucor's Series B round at $68.6 mln
Inocucor Corp, a developer of biological inputs for high-value produce and row crops, has raised an additional $20 million (US$15.9 million) for its Series B financing. The final tranche, which brings the round to about $68.6 million (US$54.4 million) in total, was backed by existing investors Cycle Capital Management, Desjardins Innovatech, TPG ART and Pontifax AgTech. Concurrently, Pontifax AgTech's Ben Belldegrun has joined the board. Founded in 2007 in Montréal, Inocucor is preparing to occupy its U.S. headquarters. Earlier this week, the company announced its buy of ATP Nutrition, a Canadian plant nutrients supplier.
19 April 2018•3 mins read
